$LDOS

Leidos to support extended ARTEMIS airborne ISR mission for U.S. Army

Leidos (LDOS) won a $127M U.S. Army contract to extend ARTEMIS airborne ISR mission through 2027, with option years. The contract supports intelligence, surveillance, and reconnaissance operations in Europe and other regions. Leidos provides the aircraft, systems, and services. The contract aligns with Leidos' NorthStar 2030 strategy, expanding its Defense Tech and Mission & Digital Solutions portfolio.

Original reporting
Published Sep 22, 2026, 5:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 5:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Leidos to support extended ARTEMIS airborne ISR mission for U.S. Army — source image
Decision brief

The 30-second read

$LDOSBullishMed
01

Why it matters

The $127 M contract is a material revenue boost and may improve Leidos' guidance for FY2027.

02

Market read

A sizable new defense contract likely supports Leidos' stock and the broader defense sector.

03

What to watch

Potential competition from other ISR vendors could affect long‑term market share.

Relevance 9/10Novelty 8/10Timing: today

Background

Leidos has been operating the ARTEMIS platform since 2020; the new award extends the mission and adds two option years.

Company-level read

Ticker impact

$LDOSBullishHigh confidence
Context

Leidos received a new U.S. Army contract worth up to $127 million to extend its ARTEMIS ISR mission through 2027.

Expected impact

Potential upside as investors price in the new revenue stream.

Evidence & confidence

Large, newly disclosed defense contract for a mid‑cap company; market typically reacts positively to such awards.

Market effects

Boosts outlook for defense and ISR technology providers.

Positive for U.S. defense contractors operating in Europe.

Reinforces demand for airborne ISR capabilities worldwide.

Counterpoint

If the contract faces future budget cuts, the upside may be limited.

Key entities

  • Leidos Holdings, Inc.

    U.S. defense and technology contractor.

  • U.S. Army

    Awarding agency for the ARTEMIS contract.

Related articles

$LDOSMed

Leidos wins $85m Air Force contract for aerospace design

Leidos Inc. secured an $85M contract from the U.S. Department of War for aerospace systems design research, running through 2036. The contract includes vehicle system design and thermal management research, with initial funding of $75,000 from fiscal 2026. Eight companies competed for the contract, awarded by the Air Force Research Laboratory.

$LDOSMedAI 9/10

Infrastructure Acquisition. Is This a Quiet AI Winner?

Leidos (NYSE: LDOS) reported Q3 revenue of $4.6B (+7% YoY) and raised 2026 guidance to $18.2B-$18.4B revenue, $12.20-$12.50 EPS. It acquired ENTRUST for $2.4B, expanding energy infrastructure. Near-term margins may dip due to acquisition costs, but long-term growth is expected from AI data center energy demand.

$AZNHighAI 8/10

AstraZeneca, Leidos, Expeditors International: CNBC ‘Final Trades’ - Expeditors International (NYSE:EXPD)

CNBC's 'Final Trades' featured picks from Jim Lebenthal (AstraZeneca, AZN), Stephen Weiss (Leidos, LDOS), Liz Thomas (Treasuries), and Joseph Terranova (Expeditors, EXPD). AZN reported regulatory approvals and strong trial data, LDOS beat Q2 estimates and raised guidance, and EXPD also exceeded Q2 expectations. Shares of AZN, LDOS, and EXPD rose 2.3%, 3.1%, and 0.5% respectively on Monday.

$LDOSMedAI 9/10

LDOS Looks 22.8% Undervalued on GF Value™

Leidos Holdings Inc (LDOS) secured an $875M contract extension from the U.S. Navy. The stock is trading at $132.83, 22.8% below its GF Value™ of $171.99, indicating undervaluation. LDOS has a GF Score™ of 78/100, reflecting strong financial health and profitability. Insiders sold $3.2M in shares over the past year.